Placebo News and Research

RSS

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca today announced that the U.S. Food and Drug Administration approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

7 Apr 2011

Positive data from PROCHIEVE vaginal progesterone Phase III study published in peer-reviewed journal

Columbia Laboratories, Inc., and Watson Pharmaceuticals, Inc., today announced the publication of Phase III PROCHIEVE® (progesterone gel) data in today's online version of Ultrasound in Obstetrics & Gynecology, the leading peer-reviewed journal of the International Society of Ultrasound in Obstetrics & Gynecology.

7 Apr 2011

Progesterone gel can reduce preterm birth in women with short cervix

A groundbreaking clinical study of a new method for preventing premature birth in millions of women each year, published in the medical journal Ultrasound in Obstetrics & Gynecology, shows that the rate of early preterm delivery in women can be reduced by 45 percent - simply by treating pregnant women at risk with a low-cost gel of natural progesterone during the midtrimester of pregnancy until term.

7 Apr 2011

Progesterone benefits women with short cervix, finds NIH study

A National Institutes of Health study has found that progesterone, a naturally occurring hormone, reduced the rate of preterm birth before the 33rd week of pregnancy by 45 percent among one category of at risk women.

7 Apr 2011

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms.

7 Apr 2011

Strawberries for prevention of esophageal cancer: Study

According to a preliminary study released Wednesday, strawberries have the potential to prevent esophageal cancer. Researchers, led by Ohio State University have shown that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months. Study's lead researcher, Tong Chen, an assistant professor in the oncology division of Ohio State University, presented the study at the American Association for Cancer Research's annual meeting.

6 Apr 2011

Estrogen therapy for menopause, study looks at risks-benefits

...

6 Apr 2011

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today announced that it has successfully completed two Phase 1a clinical studies for AVL-292, its orally-available, selective inhibitor of Bruton's tyrosine kinase (Btk).

6 Apr 2011

Strawberries may slow progression of precancerous lesions in the esophagus

Freeze-dried strawberries may be an alternative to drugs for the prevention of esophageal cancer, according to research presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

6 Apr 2011

Lupin grants Salix exclusive worldwide rights to rifaximin

Salix Pharmaceuticals, Ltd. today announced that as of March 31, 2011 Lupin Ltd. granted Salix exclusive worldwide rights (except for India) to exploit Lupin technology and technology jointly developed by Lupin and Salix for all rifaximin products for human use. This agreement expands the collaboration that Salix and Lupin entered into as of September 30, 2009.

6 Apr 2011

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.

6 Apr 2011

Neurocrine completes NBI-98854 Phase IIa study in schizophrenia patients with dyskinesia

Neurocrine Biosciences, Inc. announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor, NBI-98854.

6 Apr 2011

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Genzyme Corp., a subsidiary of sanofi-aventis Group, and Isis Pharmaceuticals Inc. announced today that data from two phase 3 studies of mipomersen in patients who had high cholesterol levels while on lipid-lowering therapy were presented at the American College of Cardiology's 60th Annual Scientific Session.

6 Apr 2011

Meditation for pain succeeds: Study

According to a new study meditation may help in reducing pain. For the study researchers mildly burned 15 men and women in a lab on two separate occasions, before and after the volunteers attended four 20-minute meditation training sessions over the course of four days. During the second round, when the participants were instructed to meditate, they rated the exact same pain stimulus - a 120-degree heat on their calves - as being 57 percent less unpleasant and 40 percent less intense, on average.

5 Apr 2011

Estrogen only hormone replacement not so risky after 50’s: Study

According to a new study hormone therapy may not be as risky for elder women as earlier thought. This comes from the Women's Health Initiative, a federally funded trial that tracked thousands of women taking hormones or placebo pills for years. The WHI looked at women who have had hysterectomies or have had their uterus removed and thus can take estrogen unaccompanied by another hormone, progestin. It found that a heightened risk of stroke from taking estrogen faded with time, while a reduced risk of breast cancer held steady.

5 Apr 2011

Individual’s response to alcohol can predict future drinking behavior

For some people, alcohol is a social lubricant. For others, it's an unpleasant downer. New research shows that a person's response to alcohol can predict their future drinking behavior, including their frequency of binge drinking and the risk of developing an alcohol-use disorder.

5 Apr 2011

Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.

5 Apr 2011

Placebo News and Research

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

Positive data from PROCHIEVE vaginal progesterone Phase III study published in peer-reviewed journal

Progesterone gel can reduce preterm birth in women with short cervix

Progesterone benefits women with short cervix, finds NIH study

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

Strawberries for prevention of esophageal cancer: Study

Estrogen therapy for menopause, study looks at risks-benefits

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

Strawberries may slow progression of precancerous lesions in the esophagus

Lupin grants Salix exclusive worldwide rights to rifaximin

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

Neurocrine completes NBI-98854 Phase IIa study in schizophrenia patients with dyskinesia

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Meditation for pain succeeds: Study

Estrogen only hormone replacement not so risky after 50’s: Study

Individual’s response to alcohol can predict future drinking behavior

Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Current Alzheimer Research publishes ExonHit's EHT 0202 Phase IIa results

Cardioxyl's CXL-1020 preclinical data against heart failure presented at ACC meeting

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News